News Archive

Lab Space industry analysis included the latest data on revenue numbers, product information and earnings of the major firms. The data includes a breakdown of earnings for the Lab Space international marketplace and a forecast for exactly that same period. This report also includes the most important business strategies that have been identified by the key players in the global Lab Space marketplace. The report also highlights the risks and strengths of key competitors in the global Lab Space market. The market’s vital information is provided by the study on Worldwide Lab Space Market 2021. This report covers all the current facts about Lab Space marketplace, which is crucial in helping to foster this market. A comprehensive assessment of the Lab Space marketplace’s dynamic background is provided at the end of the research.

As the world waits for the results of the investigation into the Wuhan biosafety laboratory and the verification of the COVID-19 origin , experts are turning to other high-security biological research facilities with a renewed interest. The Wuhan lab is only one of many around the world, but where are these other facilities? What are they working on? And most importantly, what security procedures are in place to keep future pandemics from happening?

Image: https://schar.gmu.edu/

Emergent BioSolutions (EBS +1.1%) has gained in morning hours after the company announced that a government agency exercised an option to extend a contract term related to its supply of Smallpox vaccine into the U.S. Strategic National Stockpile (SNS). The Office of the Assistant Secretary for Preparedness and Response (“ASPR”), part of the U.S. Department of Health and Human Services (“HHS”), has modified the contract with the exercise of the second of nine annual contract term extension options, the company said.

Image: https://seekingalpha.com

The deal is expected to close this calendar year.

With the opening of its state-of-the-art facility in Rockville in 2017, GSK has been strengthening its manufacturing presence in the US. As a result, the site’s portfolio of programs and bulk production has been growing steadily, with many immediate full-time job openings at the site. BioBuzz recently hosted a Virtual Recruitment Event for job-seekers to learn more about the various roles at GSK Rockville BioPharm, its work culture, and what the company is looking for in prospective employees.

Improving university/corporate research partnerships is key to advancing US competitiveness. Reform of the IRS rules surrounding corporate sponsored research taking place in university facilities funded by tax-exempt bonds has long been sought by the higher education community and will stimulate more public-private partnerships. With Congress considering new ways to fund research through a new NSF Technology Directorate and the possibility of a large infrastructure package, an opportunity is now open for Congress to address these long-standing reforms in IRS rules.

BUFFALO, N.Y.–(BUSINESS WIRE)–Emerge Capital Management (“Emerge”) has officially launched EMPWR, an emerging managers program. Emerge’s EMPWR program includes a roster of elite, emerging portfolio managers with a special focus on women portfolio managers. It provides full back-office support, platform support, and ESG monitoring dedicated to high performance.

NEWARK, Del., July 14, 2021 /PRNewswire/ — Today, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) confirms that it has received $153M in new funding from the National Institute of Standards and Technology (NIST) as announced by U.S. Commerce Secretary Gina Raimondo at NIIMBL’s National Meeting in Washington, DC. The two awards include $70M to continue federal funding for NIIMBL for an additional five years and an additional $83M for coronavirus response projects under the American Rescue Plan (ARP).

BUFFALO, N.Y.–(BUSINESS WIRE)–Emerge Capital Management (“Emerge”) has officially launched EMPWR, an emerging managers program. Emerge’s EMPWR program includes a roster of elite, emerging portfolio managers with a special focus on women portfolio managers. It provides full back-office support, platform support, and ESG monitoring dedicated to high performance. 

“What’s important is that we are focusing on top performing managers who would earn their place at the table not just because they are wonderful, talented women, but because they are strong credible portfolio managers”  Tweet this 

BALTIMORE, July 14, 2021 /PRNewswire/ — CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System, the world’s first and only ultrasound gastrostomy system that allows physicians to place gastrostomy tubes at the point of care, using solely ultrasound imaging.

The PUMA System™ is a new category of minimally invasive devices, enabling ultrasound to be used for procedures in hollow organs of the body where previously it was impossible or unsafe to do so. The first application of the PUMA platform technology, the PUMA-G System, is an FDA-cleared procedural kit allowing bedside clinicians, rather than consultant specialists, to place gastrostomy tubes using solely ultrasound and their existing skill sets and team. With CE Mark approval, the PUMA-G System now has the potential to improve efficiency, safety, and cost-effectiveness on an international level. CoapTech plans to begin a targeted launch in Europe later this year.